Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | MGMT | P16455 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24920307 | 0.89 | TSHR (0.35) | TSHRCRBNHPSECA2CA9 | |
| SCHEMBL19138454 | 0.87 | CA2 (0.39) | CRBNCA2CA9CA12CA1 | |
| SCHEMBL15076070 | 0.86 | SLC6A5 (0.40) | TSHRCRBNHPSETTRTPSAB1 | |
| SCHEMBL14886284 | 0.85 | CRBN (0.31) | CRBN | |
| SCHEMBL25356799 | 0.85 | CRBN (0.34) | TSHRCRBNCA2CA9CA12 | |
| SCHEMBL24629997 | 0.84 | CASP2 (0.49) | — | |
| SCHEMBL22512052 | 0.83 | MGMT (0.34) | CRBNMGMT | |
| SCHEMBL30808826 | 0.83 | MGMT (0.34) | CRBNMGMT | |
| SCHEMBL29649573 | 0.83 | MGMT (0.34) | CRBNMGMT | |
| SCHEMBL25774033 | 0.83 | MGMT (0.34) | CRBNMGMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | TSHR 2354/4885CRBN 642/4885HPSE 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.